Regulatory & Legal

Allarity Therapeutics lands a crucial $20M debt deal to push its unique ovarian cancer drug, stenoparib, through late-stage trials and extend its runway to 2028.

AIRO Group will present its future vision at a major tech conference, facing investor scrutiny amid ambitious growth plans and recent financial hurdles.

Brazilian aerospace giant Embraer shatters financial records and builds its largest-ever order book, signaling a robust recovery in global aviation.

With key lithium projects advancing from Mali to Argentina, LRC's portfolio updates signal a ramp-up in global supply for the electric vehicle revolution.

MEXC Foundation and UNCB launch MEXCampus at UNSW, a new program teaching crypto trading to students, sparking a debate on opportunity versus risk.

As Sweden nears smoke-free status with nicotine pouches, Argentina's ban on alternatives leaves millions of women at risk. A new report ignites the debate.

A Hong Kong professor's tech, inspired by desert ants, is cooling cities globally without electricity, slashing energy use and carbon emissions.

A new anti-cheat system promises fair tables and real value for no-deposit bonuses, but can it solve crypto poker's deep-rooted integrity crisis?

From Cairo to Hollywood, NYFA alumni and faculty are behind Oscar-nominated films and four international submissions, cementing the school's global impact.

After a major clinical trial failure, COSCIENS is shutting down its German pharma unit to focus on its profitable plant-based active ingredients business.

An oversubscribed offering provides a critical cash infusion for RER's Wyoming projects, but market skepticism and permitting hurdles test its long journey.

Praxis Solutions' new WealthHawk platform uses AI to find clients at key life events, aiming to end cold calling and solve the organic growth puzzle.

Indianapolis utility's parent asks investors to amend debt terms to prevent costly triggers in its massive take-private deal with GIP and EQT.

aTyr Pharma heads to a crucial FDA meeting for its lung drug efzofitimod, which missed its main goal but showed significant patient quality-of-life gains.

Weebit Nano's advanced memory is at the heart of a South Korean national program aiming to revolutionize AI with ultra-low-power compute-in-memory chips.

Outraged by Canada's enduring water crisis, Quebec high school students are taking their fight for Indigenous rights to the nation's capital.

With a strong cash position, ArriVent pushes its lead lung cancer drug toward a mid-2026 data readout while building a new pipeline in ADCs.

Scientists find herpes melts the inside of our cells to replicate faster, a discovery that could revolutionize treatments for a host of viral diseases.

New preclinical data shows Quanta Therapeutics' inhibitors remain potent against cancers that have developed resistance to advanced pan-RAS treatments.

Seal Shield's strategic acquisition of Vioguard and its FDA-cleared UV-C tech marks a major step forward in the battle against healthcare-associated infections.